Dear Editor, Clusterin (CLU) is a secreted heterodimeric glycoprotein that can be produced almost ubiquitously in mammalians tissues.
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Its gene expression is subjected to complex regulation and can change enormously according to different stimuli. 2 Cloned and identified as the most potently induced gene in the regressing rat ventral prostate following androgen-ablation, 3 CLU was almost simultaneously characterized and isolated by different research groups working in widely divergent areas. 2 CLU is coded by a single copy gene, located on chromosome 8. 4 The gene codes for an initial precursor peptide glycosylated and cleaved into two a and b chains of 40 kDa each, held together by a unique five disulfide bond motif in the extracellular mature form. 1 This secreted form of CLU has been suggested to act as a molecular chaperone following stress-induced injury, 5 clearing extracellular debris. 6 However, it has been reported the existence of an inactive, cytoplasmic form of CLU produced by alternative splicing that is converted by ionizing irradiation to a truncated mature nuclear isoform, 7 which binds the Ku70/Ku80 complex in cell-free systems 8 inhibiting cell growth and survival 7 probably by a caspase-3-independent mechanism. 9 Other alternative CLU isoforms, produced either by exon skipping 10 or by post-translational modifications activated by apoptosis, 11, 12 were recently described. These different isoforms of CLU have been suggested to be antiapoptotic 6, 13 or proapoptotic. 7, 10, 12, [14] [15] [16] These controversial reports on the role of CLU might be related to specific proteomic profiles that are produced by different apoptotic stimuli (i.e. the general protein pattern of CLU and the relative ratio between different CLU isoforms). This might explain why CLU has been involved in a plethora of pathophysiological processes, including cell-cell and cellmatrix adhesion, cell differentiation, transformation, aging 17, 18 and cancer, 19 but its biological role still remains to be clearly established. Reports suggesting that CLU may be a potential tumor suppressor gene include the finding that CLU suppresses NF-kB activity and the metastatic phenotype of neuroblastoma cells. 20 We have previously reported that CLU overexpression inhibits cell cycle progression of simian virus 40(SV40)-immortalized human prostate PNT2 and PNT1A epithelial cells. 21 To further assess the role of CLU in apoptotic processes we have studied its expression pattern during the regulation of calcium homeostasis. Ca 2 þ is an important regulator of apoptosis and cell survival. 22, 23, 24 Both pathological increase of Ca 2 þ concentration in the cytosol compartment by inophores 25 and depletion of intracellular Ca 2 þ stores may trigger apoptosis by disrupting intracellular architecture and allowing effectors to gain access to their substrates. 24, 26, 27 Activation of apoptotic endonucleases 28 eliciting DNA cleavage and chromatin condensation has been well documented. 29, 30, 31 A tight buffering of intracellular Ca 2 þ is required for normal growth. In fact, apoptosis can be induced by Ca 2 þ mobilization from intracellular pools, 23, 24, 27 chelation of intracellular Ca -tetra-acetic acid tetra-acetoxymethyl ester (BAPTA-AM) 28, 29 or removal of extracellular Ca 2 þ . 32 Intracellular Ca 2 þ deficiency regulates gene expression 22, 26 and induces apoptosis through caspases activation. 23, 27, 33 It has been shown that extracellular Ca 2 þ depletion reduces expression of CLU mRNA, but its proteomic profile has not been studied. 26 Thus, we decided to study the effect of Ca 2 þ depletion in prostate cells and its effect on CLU protein expression and localization.
We compared the cell proliferation rate of PNT1A cells grown under standard culture medium (RPMI plus 10% foetal bovine serum, FBS), keratinocyte serum-free complete medium 34 (KSFM, which has subphysiological concentrations of Ca 2 þ , 0.1 mM), or KSFM supplemented with 1.8 mM Ca 2 þ (Figure 1a ). Under these condition, as previously reported, 35 KSFM caused a marked inhibition of cell growth rate when compared to standard culture conditions, inducing anoikis (cell detachment followed by chromatin condensation). Addition of either 1.8 mM Ca 2 þ or the caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-flu-oromethylketone (z-VAD-fmk, 1 mM) to KSFM medium completely rescued PNT1A cells and prevented cell detachment and anoikis induction ( Figure 1a ). After 8 days of culture in KSFM medium supplemented with z-VAD-fmk, cells reached a density similar to that observed under standard conditions ( Figure 1a ). In PNT1A cells CLU expression was detected by Western blot assay with a commercially available mouse monoclonal antibody from Upstate Biotechnology (clone 41D). The prevailing form of CLU in the cells consists of a 65 kDa intracellular CLU precursor that is progressively converted to low-molecular weight and secreted CLU forms. 36 Upon KSFM incubation, the 65 kDa CLU precursor is rapidly converted to a 45 kDa CLU isoform that accumulates in parallel to poly(ADP-ribose) . To assess whether intracellular Ca 2 þ depletion would per se cause apoptosis, we cultured PNT1A cells in the presence of BAPTA-AM, a well-known intracellular Ca 2 þ blocker 26 that can trigger activation of caspases and apoptosis. 23, 28, 29, 33 Cell proliferation was assessed by crystal violet staining method in the presence of 20 mM BAPTA-AM. As soon as 4 h after treatment, cells growth was significantly inhibited reaching about 55 and 78% inhibition at 24 and 48 h (Po0.01, data not shown), respectively, in strict association with chromatin condensation and fragmentation, cell rounding and detachment, hallmarks of anoikis (see Figure 1e , RPMI þ BAPTA-AM). Consistently with the hypothesis that changes in the intracellular availability of Ca 2 þ could trigger anoikis in PNT1A cells, a switch to the 45 kDa isoform of CLU was already observed 4 h after the beginning of BAPTA-AM administration, a time when caspase-9 activation started to be evident (Figure 1c Immunocytochemical analysis of PNT1A cells showed subcellular localization of CLU under different experimental conditions. We compared the commercially available mouse monoclonal anti-CLU antibody and an affinity-purified polyclonal anti-human CLU antibody (a-324) that we have raised against an epitope located on the a-subunit of human CLU protein at position 324-341 (Accession Number X14723, cfr. legend to Figure 1 ). Experiments were conducted in parallel with cells grown in standard RPMI or in KSFM medium (Figure 1d ). Western blot analysis using the a-324 antibody confirmed the detection of the 45 kDa nuclear CLU isoform in cells grown in KSFM medium (data not shown). Under standard conditions, CLU was detectable in the cytoplasm (Figure 1d, RPMI 2 and 8 days) . Conversely, CLU was detected in the nucleus already 2 days after KSFM-growth (Figure 1d, KSFM) . Detection of CLU in the nucleus preceded cell morphological changes. After 8 days in KSFM medium, nuclear CLU accumulated into apoptotic bodies (Figure 1d , KSFM). The comparison between the two antibodies showed that a-324 gave better results when compared to the commercially available mouse monoclonal anti-CLU antibody (Figure 1d , compare a-324 and Upstate). When KSFM was supplemented with 1.8 mM Ca 2 þ , CLU was clearly localized in the cytoplasm (Figure 1e , KSFM þ Ca 2 þ , 2 and 8 days), and cells growth rates ( Figure 1a ) and cell cycle progression (Figure 1e , subpanels 1 and 2) were identical to that observed under standard growth conditions (2 days RPMI). As expected, BAPTA-AM administration caused a dramatic reduction in cell growth (data not shown) and viability ( Figure 1e , RPMI þ BAPTA-AM, subpanels 1 and 2). Fluorescence activated cell sorting (FACS) analysis revealed a progressive loss of the G 0 /G 1 fraction in concomitance to an increase of the subdiploid peak (Figure 1e , RPMI þ BAPTA-AM, subpanels 1 and 2). When cells were incubated in KSFM þ z-VAD-fmk for 2 days, CLU was detected into the nuclei (Figure 1e , KSFM þ z-VAD, 2 days), but DNA fragmentation was blocked (Figure 1e , KSFM þ z-VAD, subpanels 1 and 2). At 8-day culturing, clusterin was almost completely detected into the cytoplasm (Figure 1e , KSFM þ z-VAD, 8 days), a time when cells were completely rescued and cell growth rate was very similar to controls and significantly higher than that observed in KSFM alone (Figure 1a) . Anoikis induction and 2 þ or z-VAD-fmk administration prevents whereas calcium chelation induces accumulation of nuclear CLU and anoikis in PNT1A cells. Cells were cultured in KSFM þ Ca 2 þ for 2 and 8 days, fixed, and subjected to immunocytochemistry (magnification: Â 20), as reported above, with the a-324 antibody. Cells were cultured with 20 mM BAPTA-AM for 4 or 24 h, fixed and subjected to immunocytochemistry (magnification: Â 40). Cells were grown in the presence of KSFM þ z-VAD for 2 or 8 days, fixed, and subjected to immunocytochemistry (magnification: Â 20) . FACS analysis of cell cycle progression was performed as previously described. 21 Values are the mean of cell population (% of total)7S.D. (n ¼ 5). Significant differences versus 2 days RPMI (G 0 /G 1 , 35%71; S, 20%73; G 2 /M, 12%73; Subdiploid, 33%75) are indicated (*Po0.05, **Po0.01). Effects of overexpression of intra-CLU on cell proliferation and apoptosis. (f, top panel) Cells were transfected with either pIREShyg1 containing the intra-CLU cDNA, or empty pIRES-hyg1 expression vector (mock control). 41 Cells were harvested after 24 h (lanes 1) and 48 h (lanes 2), and subjected to Western blot analysis with the a-324 antibody. To directly demonstrate that nuclear localization of CLU can induce anoikis, we transfected PNT1A cells with an expression vector containing a shortened CLU cDNA (intra-CLU) that starts from nucleotide 152 and therefore lacks the hydrophobic secretion signal sequence. Following transient transfection, PNT1A cells showed a detectable suppression of cell proliferation (data not shown) and decreased viability in association to a progressive accumulation of intra-CLU (49 kDa, Figure 1f, top) . Intra-CLU accumulated in the nuclei of about 75% of transfected cells (Figure 1f, bottom) . Notably, expression of nuclear CLU induced a significant increase in caspase-3 activity (Figure 1g ), DNA fragmentation (Figure 1h ) and cell detachment. Nuclear CLU caused cell death by activation of caspase-dependent apoptosis. In fact, z-VADfmk significantly rescued cells from anoikis and DNA fragmentation (Figure 1g and h, intra-CLU þ z-VAD versus mock).
We report here that calcium (Ca 2 þ ) deprivation causes translocation of a 45 kDa CLU isoform to the nucleus in human prostate epithelial cells, leading to inhibition of cell proliferation and caspase-cascade-dependent anoikis. Our data show that accumulation of nuclear CLU caused induction of apoptosis and anoikis in prostate cells, and that conditions restoring normal cell growth and survival also cause relocalization of CLU in the cytoplasm. In fact, early before induction of anoikis, we observed translocation of a 45 kDa CLU isoform in the cell nuclei that was prevented by Ca 2 þ or z-VAD-fmk supplementation, leading to cell rescue. Importantly, transient overexpression of an intracellular, not secreted, form of CLU accumulating into the nucleus caused cell growth inhibition and anoikis in the absence of Ca 2 þ deprivation. This effect was also caspase-dependent. In any condition studied, cell demise was strictly associated with translocation of CLU to the nucleus. Taken together, these data suggest that anoikis-death by Ca 2 þ deprivation is accompanied by nuclear translocation of a 45 kDa CLU and that a nuclear only form of CLU appears to recapitulate death by Ca 2 þ deprivation, suggesting a putative causative link between Ca 2 þ depletion, CLU nuclear translocation and cell death. CLU intracellular trafficking can now be linked to Ca 2 þ signalling pathway, resulting in regulation of survival and proliferation of androgen-dependent prostate epithelial cells. Moreover, the data here presented and previous results showing that CLU is downregulated during prostate cancer progression 19, 37 support the hypothesis that CLU is a tumorsuppressor gene for the prostate. The finding that calreticulin, an intracellular Ca 2 þ -binding protein, is regulated by androgens, 38 and that inhibition of spontaneous and androgeninduced prostate growth by a vitamin D analog involves CLU, 39 also supports the hypothesis that a causative link between these pathways may exist.
Identification of the molecular mechanisms involved in the production and processing of intra-CLU will help in the future the molecular characterization of prostate cancer, one of the most diffuse and elusive type of cancer.
